Conference Proceedings
Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial
Jason R Westin, Constantine S Tam, Peter Borchmann, Ulrich Jaeger, Joseph P McGuirk, Harald Holte, Edmund K Waller, Samantha Jaglowski, Michael R Bishop, Charalambos Andreadis, Stephen Ronan Foley, Isabelle Fleury, P Joy Ho, Stephan Mielke, Takanori Teshima, Stephen J Schuster, Veronika Bachanova, Richard T Maziarz, Koen Van Besien, Koji Izutsu Show all
BLOOD | AMER SOC HEMATOLOGY | Published : 2019
Abstract
Background: Tisagenlecleucel, an anti-CD19 chimeric antigen receptor (CAR)-T cell therapy, has demonstrated durable responses and a manageable safety profile in adult patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). We report the correlation of pre- and post-infusion factors and biomarkers with efficacy in tisagenlecleucel-treated pts with r/r DLBCL. Methods: Results from JULIET, a global, single-arm, pivotal, phase 2 trial of tisagenlecleucel in adult pts with r/r DLBCL, were analyzed to identify baseline disease and pt characteristics and serum biomarkers that may correlate with efficacy. The relationships between markers such as lactate deh..
View full abstract